What Is Tirzepatide?
Reviewed by Gabriel Brocklesby · Last updated
Tirzepatide is a dual GIP and GLP-1 receptor agonist — a novel mechanism that distinguishes it from earlier GLP-1 drugs like semaglutide. By targeting both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously, tirzepatide has shown strong efficacy in clinical trials for both blood sugar regulation and weight management.
It was developed by Eli Lilly and approved under the brand name Mounjaro for type 2 diabetes management, and subsequently as Zepbound for chronic weight management in adults with obesity or weight-related conditions. Like semaglutide, it is administered by subcutaneous injection once weekly.
Clinical trial data for tirzepatide has shown substantial weight loss outcomes, with some participants achieving reductions that exceed those seen in semaglutide trials. However, direct head-to-head comparison between the two drugs in large randomised controlled trials is limited, and individual responses vary significantly.
Clinics offering tirzepatide should provide a full medical assessment before prescribing, including a review of cardiovascular history, metabolic markers, and any contraindications. Side effects are broadly similar to other GLP-1 class drugs and include gastrointestinal symptoms particularly during dose escalation.
When comparing clinics offering tirzepatide, look for transparent prescriber credentials, a structured intake process, and clear follow-up protocols. Be cautious of providers offering rapid or assessment-free access.
This page is informational only. Peptide Clinic Finder does not prescribe or sell tirzepatide. Use this directory to compare clinic listings and contact providers directly.
Who this guide is for
This guide is for users comparing higher-intensity GLP-1-related pathways and trying to understand how tirzepatide differs from semaglutide in clinical use, access, pricing, and provider support.
Why patients compare it
Patients often compare tirzepatide when they want to understand programme intensity, pricing, expected tolerability, and whether a clinic uses a more structured metabolic-health model.
Safety and buying context
A clinic should be able to explain why tirzepatide is being considered, how dose escalation is supervised, and what support is provided if gastrointestinal side effects or access issues arise.
Frequently asked questions
What is tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist used for blood sugar regulation and weight management. It differs from semaglutide by targeting two hormone receptors rather than one.
How does tirzepatide differ from semaglutide?
Tirzepatide targets both GLP-1 and GIP receptors while semaglutide targets GLP-1 only. Clinical trials have shown strong weight loss outcomes for tirzepatide though individual responses vary.
Where can I find a tirzepatide clinic?
Peptide Clinic Finder lists clinics offering tirzepatide across the US and UK. Compare providers by consultation model, clinician credentials, and monitoring protocols.
Next step
Compare clinics offering this treatment
Use city pages, treatment comparisons, and clinic listings together. That gives you a better view of programme quality, pricing context, and oversight than reading a guide in isolation.
Continue researching
Curated pricing and clinic research
Pricing comparisons
Treatment context
For clinics
Are you a clinic?
Get featured on this page and reach patients actively looking for peptide therapy, GLP-1 treatments, recovery support, and longevity care.